Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2013-02-27

FDA Approved: RIFADIN IV — Supplemental Application (Sanofi-Aventis U.S. LLC)

View source ↗

Summary

FDA approved a supplemental application to add an intravenous formulation of Rifadin (rifampin) from Sanofi-Aventis U.S. LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RIFADIN IV (rifampin)

Snippet

SUPPL AP for RIFADIN IV (RIFAMPIN)